Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancerPier‐Luc Clermont, Cheryl D. Helgason, Yan Ting Chiang et al.|Clinical Epigenetics|2016Cited by 78
EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell linesMaryam Latarani, Francesco Crea|Epigenomics|2025Cited by 4
EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive-variant prostate cancerMaryam Latarani, Francesco Crea|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 1